Frederick J. Raal, South Africa
University of the Witwatersrand Faculty of Health Sciences
Presenter of 3 Presentations
Live Q&A
Session Type
Late breaker
Session Time
16:00 - 17:00
Lecture Time
16:42 - 16:57
[{"name":"Live Q&A","mode":"playlist","public":true,"info":{"id":1768,"presentation":"Live Q&A","session":"Late breaker session 1","presenter":"Frederick J. Raal, South Africa, Kausik K. Ray, United Kingdom, Evan A. Stein, United States of America, Luiz Sergio F. De Carvalho, Brazil, Alexey N. Meshkov, Russian Federation, Christoph S\u00e4ly, ","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/eas20\/persons\/photos\/1332.jpg"},"playlist":[{"name":"Late breaker session 1","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/14\/Late breaker session 1.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/14\/Late breaker session 1.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/14\/A4660C7D.jpg","data":[],"tracks":[]}]}]
{"provider":"CTI","provider_live":0,"type":1,"code":"9E22Xi0wu"}
[session]
[presentation]
[presenter]
Inclisiran reduces LDL-cholesterol independent of genotype in subjects with heterozygous familial hypercholesterolaemia
Session Type
Late breaker
Session Time
16:00 - 17:00
Lecture Time
16:00 - 16:07
[{"name":"Inclisiran reduces LDL-cholesterol independent of genotype in subjects with heterozygous familial hypercholesterolaemia","mode":"playlist","public":true,"info":{"id":1707,"presentation":"Inclisiran reduces LDL-cholesterol independent of genotype in subjects with heterozygous familial hypercholesterolaemia","session":"Late breaker session 1","presenter":"Frederick J. Raal, South Africa","photo":""},"playlist":[{"name":"","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/14\/Frederick Raal - EAS20 - reduces LDL cholesrerol - 1707.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/14\/Frederick Raal - EAS20 - reduces LDL cholesrerol - 1707.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/14\/597DF380.jpg","data":[],"tracks":[]}]}]
{"provider":"CTI","provider_live":0,"type":1,"code":"8E22Xi0vr"}
[session]
[presentation]
[presenter]
The Efficacy and Safety of Evinacumab in Homozygous Familial Hypercholesterolaemia (HoFH) Patients with Little to No Low-Density Lipoprotein Receptor (LDLR) Activity
Session Type
Late breaker
Session Time
16:00 - 17:00
Lecture Time
16:14 - 16:21
[{"name":"The Efficacy and Safety of Evinacumab in Homozygous Familial Hypercholesterolaemia (HoFH) Patients with Little to No Low-Density Lipoprotein Receptor (LDLR) Activity","mode":"playlist","public":true,"info":{"id":1573,"presentation":"The Efficacy and Safety of Evinacumab in Homozygous Familial Hypercholesterolaemia (HoFH) Patients with Little to No Low-Density Lipoprotein Receptor (LDLR) Activity","session":"Late breaker session 1","presenter":"Frederick J. Raal, South Africa","photo":""},"playlist":[{"name":"The Efficacy and Safety of Evinacumab in Homozygous Familial Hypercholesterolaemia (HoFH) Patients w","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/14\/Frederick Raal (Derick) - EAS20- 1573 -The Efficacy and Safety of Evinacumab in Homozygous Familial Hypercholesterolaemia (HoFH) Patients with Little to No Low-Density Lipoprotein Receptor (LDLR) Ac.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/14\/Frederick Raal (Derick) - EAS20- 1573 -The Efficacy and Safety of Evinacumab in Homozygous Familial Hypercholesterolaemia (HoFH) Patients with Little to No Low-Density Lipoprotein Receptor (LDLR) Ac.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/14\/1AD7F549.jpg","data":[],"tracks":[]}]}]
{"provider":"CTI","provider_live":0,"type":1,"code":"9E22Xi0t8"}
[session]
[presentation]
[presenter]
